EBS Emergent BioSolutions Inc.
Healthcare$9.04+0.00%OpenMarket Cap: $466.7M
As of 2026-05-26
Valuation
P/E (TTM)
7.83
PEG
0.06
P/B
0.84
P/S
0.64
EV/EBITDA
5.10
DCF Value
$2.66
FCF Yield
31.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
44.4%
Operating Margin
10.5%
Net Margin
-1.3%
ROE
-1.6%
ROA
-0.7%
ROIC
-14.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $156.1M | 43.3% | $10.5M | $6.8M | $— | — |
| Q4 null | $148.7M | 31.3% | $-16.6M | $-54.6M | $— | — |
| FY null | $742.9M | 47.2% | $110.2M | $52.6M | $— | — |
| Q3 null | $231.1M | 55.9% | $76.8M | $51.2M | $— | — |
| Q2 null | $140.9M | 40.8% | $500.0K | $-12.0M | $— | — |
| Q1 null | $222.2M | 52.4% | $48.6M | $68.0M | $— | — |
| Q4 null | $194.7M | 70.1% | $-9.5M | $-31.3M | $— | — |
| FY null | $1.04B | 36.0% | $-108.7M | $-190.6M | $— | — |
| Q3 null | $293.8M | 55.9% | $64.5M | $114.8M | $— | — |
| Q2 null | $254.7M | -25.7% | $-203.5M | $-283.1M | $— | — |
| Q1 null | $300.4M | 46.9% | $39.8M | $9.0M | $— | — |
| Q4 2023 | $276.6M | 61.2% | $-43.8M | $-49.5M | $-0.95 | — |